Characterization of BU09059: A novel potent selective κ-receptor antagonist

ACS Chemical Neuroscience

Volumn 5, Issue 3, 2014, Pages 177-184

  Casal Dominguez, Joseph J ^a   Furkert, Daniel ^a   Ostovar, Mehrnoosh ^a   Teintang, Linnea ^a   Clark, Mary J ^b   Traynor, John R ^b   Husbands, Stephen M ^a   Bailey, Sarah J ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

CD 1 mouse; kappa antagonist; kappa opioid receptor; mu antagonist; norBNI; tail withdrawal assay

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ALPHA ADRENERGIC RECEPTOR; BU 09057; BU 09058; BU 09059; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR; OPIATE RECEPTOR; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG; 17-CYCLOPROPYLMETHYL-6,7-DIDEHYDRO-4,5-EPOXY-5'-GUANIDINYL-3,14-DIHYDROXYINDOLO(2',3'-6,7)MORPHINAN; 7-HYDROXY-N-(1-((4-(3-HYDROXYPHENYL)-3,4-DIMETHYL-1-PIPERIDINYL)METHYL)-2-METHYLPROPYL)-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBOXAMIDE; BU09059; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GUANIDINE DERIVATIVE; ISOQUINOLINE DERIVATIVE; KAPPA OPIATE RECEPTOR; MORPHINAN DERIVATIVE; NALTREXONE; NARCOTIC ANTAGONIST; NORBINALTORPHIMINE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GUINEA PIG; HUMAN; ILEUM; IN VITRO STUDY; INBRED MOUSE STRAIN; METABOLISM; NOCICEPTION; PHYSIOLOGY; RAT; SYNTHESIS; TUMOR CELL LINE; VAS DEFERENS;

ANIMALS; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, D-PENICILLAMINE (2,5)-; GUANIDINES; GUINEA PIGS; HUMANS; ILEUM; IN VITRO TECHNIQUES; ISOQUINOLINES; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; MORPHINANS; NALTREXONE; NARCOTIC ANTAGONISTS; NOCICEPTION; PIPERIDINES; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; TETRAHYDROISOQUINOLINES; VAS DEFERENS;

EID: 84896472493     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn4001507     Document Type: Article

References (46)

1. Schwarzer, C. (2009) 30 years of dynorphins-New insights on their functions in neuropsychiatric diseases Pharmacol. Ther. 123, 353-370
2. Mansour, A., Fox, C. A., Burke, S., Meng, F., Thompson, R. C., Akil, H., and Watson, S. J. (1994) Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study J. Comp. Neurol. 350, 412-438
3. Kitchen, I., Slowe, S. J., Matthes, H. W. D., and Kieffer, B. (1997) Quantitative autoradiographic mapping of μ-, δ- and κ-opioid receptors in knockout mice lacking the μ-opioid receptor gene Brain Res. 778, 73-88
4. Lin, S., Boey, D., Lee, N., Schwarzer, C., Sainsbury, A., and Herzog, H. (2006) Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain Neuropeptides 40, 115-123
5. Pfeiffer, A., Brantl, V., Herz, A., and Emrich, H. M. (1986) Psychotomimesis mediated by kappa opiate receptors Science 233, 774-776
6. Todtenkopf, M. S., Marcus, J. F., Portoghese, P. S., and Carlezon, W. A., Jr. (2004) Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats Psychopharmacology 172, 463-470
7. Carlezon, W. A., Jr., Beguin, C., DiNieri, J. A., Baumann, M. H., Richards, M. R., Todtenkopf, M. S., Rothman, R. B., Ma, Z., Lee, D. Y., and Cohen, B. M. (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats J. Pharmacol. Exp. Ther. 316, 440-447
8. McLaughlin, J. P., Marton-Popovici, M., and Chavkin, C. (2003) Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses J. Neurosci. 23, 5674-5683
9. Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jr., Jones, R. M., Portoghese, P. S., and Carlezon, W. A., Jr. (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats J. Pharmacol. Exp. Ther. 305, 323-330
10. Carlezon, W. A., Béguin, C., Knoll, A. T., and Cohen, B. M. (2009) Kappa-opioid ligands in the study and treatment of mood disorders Pharmacol. Ther. 123, 334-343
11. Bruchas, M. R., Land, B. B., and Chavkin, C. (2010) The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors Brain Res. 1314, 44-55
12. Metcalf, M. and Coop, A. (2005) Kappa opioid antagonists: Past successes and future prospects AAPS J. 7, E704-E722
13. Beguin, C. and Cohen, B. M. (2009) Medicinal Chemistry of Kappa Opioid Receptor Antagonists. In Opiate Receptors and Antagonists From Bench to Clinic; Dean, R. L., III, Bilsky, E. J., and Negus, S. S., Eds.), pp 99-118, Humana Press, Totawa, NJ.
14. Carroll, F. I. and Carlezon, W. A. (2013) Development of κ Opioid Receptor Antagonists J. Med. Chem. 56, 2178-2195
15. Carroll, I., Thomas, J. B., Dykstra, L. A., Granger, A. L., Allen, R. M., Howard, J. L., Pollard, G. T., Aceto, M. D., and Harris, L. S. (2004) Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist Eur. J. Pharmacol. 501, 111-119
16. Bruchas, M. R. and Chavkin, C. (2010) Kinase cascades and ligand-directed signaling at the kappa opioid receptor Psychopharmacology 210, 137-147
17. Melief, E. J., Miyatake, M., Carroll, F. I., Beguin, C., Carlezon, W. A., Jr., Cohen, B. M., Grimwood, S., Mitch, C. H., Rorick-Kehn, L., and Chavkin, C. (2011) Duration of action of a broad range of selective kappa-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation Mol. Pharmacol. 80, 920-929
18. Thomas, J. B., Fix, S. E., Rothman, R. B., Mascarella, S. W., Dersch, C. M., Cantrell, B. E., Zimmerman, D. M., and Carroll, F. I. (2004) Importance of phenolic address groups in opioid kappa receptor selective antagonists J. Med. Chem. 47, 1070-1073
19. Thomas, J. B., Atkinson, R. N., Rothman, R. B., Fix, S. E., Mascarella, S. W., Vinson, N. A., Xu, H., Dersch, C. M., Lu, Y. F., Cantrell, B. E., Zimmerman, D. M., and Carroll, F. I. (2001) Identification of the First trans -(3 R,4 R)- Dimethyl-4-(3-hydroxyphenyl)piperidine Derivative To Possess Highly Potent and Selective Opioid κ Receptor Antagonist Activity J. Med. Chem. 44, 2687-2690
20. Takemori, A. E., Ho, B. Y., Naeseth, J. S., and Portoghese, P. S. (1988) Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays J. Pharmacol. Exp. Ther. 246, 255-258
21. Thomas, J. B., Atkinson, R. N., Vinson, N. A., Catanzaro, J. L., Perretta, C. L., Fix, S. E., Mascarella, S. W., Rothman, R. B., Xu, H., Dersch, C. M., Cantrell, B. E., Zimmerman, D. M., and Carroll, F. I. (2003) Identification of (3 R)-7-Hydroxy- N -((1 S)-1-{[(3 R,4 R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxamide as a Novel Potent and Selective Opioid κ Receptor Antagonist J. Med. Chem. 46, 3127-3137
22. Thomas, J. B., Fall, M. J., Cooper, J. B., Rothman, R. B., Mascarella, S. W., Xu, H., Partilla, J. S., Dersch, C. M., McCullough, K. B., Cantrell, B. E., Zimmerman, D. M., and Carroll, F. I. (1998) Identification of an Opioid κ Receptor Subtype-Selective N-Substituent for (+)-(3 R,4 R)-Dimethyl-4-(3- hydroxyphenyl)piperidine J. Med. Chem. 41, 5188-5197
23. Cai, T. B., Zou, Z., Thomas, J. B., Brieaddy, L., Navarro, H. A., and Carroll, F. I. (2008) Synthesis and In Vitro Opioid Receptor Functional Antagonism of Analogues of the Selective Kappa Opioid Receptor Antagonist (3 R)-7-Hydroxy- N -((1 S)-1-{[(3 R,4 R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1- piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxamide (JDTic) J. Med. Chem. 51, 1849-1860
24. Cueva, J. P., Cai, T. B., Mascarella, S. W., Thomas, J. B., Navarro, H. n. A., and Carroll, F. I. (2009) Synthesis and In Vitro Opioid Receptor Functional Antagonism of Methyl-Substituted Analogues of (3 R)-7-Hydroxy- N -[(1 S)-1-{[(3 R,4 R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2- methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) J. Med. Chem. 52, 7463-7472
25. Casal-Dominguez, J. J., Clark, M., Traynor, J. R., Husbands, S. M., and Bailey, S. J. (2013) In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor J. Psychopharmacol. 27, 192-202
26. Endoh, T., Matsuura, H., Tanaka, C., and Nagase, H. (1992) Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo Arch. Int. Pharmacodyn. Ther. 316, 30-42
27. Glass, P. S. A., Hardman, D., Kamiyama, Y., Quill, T. J., Marton, G., Donn, K. H., Grosse, C. M., and Hermann, D. (1993) Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra-Short-Acting Opioid: Remifentanil (GI87084B) Anesth. Analg. 77, 1031-1040
28. Erhardt, P. W., Woo, C. M., Anderson, W. G., and Gorczynksi, R. J. (1982) Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function J. Med. Chem. 25, 1408-1412
29. Yang, H. S., Wu, W. M., and Bodor, N. (1995) Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers Pharm. Res. 12, 329-336
30. Hammer, R. H., Wu, W. M., Sastry, J. S., and Bodor, N. (1991) Short acting soft mydriatics Curr. Eye Res. 10, 565-570
31. Chorvat, R. J., Black, L. A., Ranade, V. V., Barcelon-Yang, C., Stout, D. M., Brown, B. S., Stampfli, H. F., and Quon, C. Y. (1993) Mono- and bis(aminomethyl)phenylacetic acid esters as short-acting antiarrhythmic agents. 2 J. Med. Chem. 36, 2494-2498
32. Verhoest, P. R., Sawant Basak, A., Parikh, V., Hayward, M., Kauffman, G. W., Paradis, V., McHardy, S. F., McLean, S., Grimwood, S., Schmidt, A. W., Vanase-Frawley, M., Freeman, J., Van Deusen, J., Cox, L., Wong, D., and Liras, S. (2011) Design and Discovery of a Selective Small Molecule kappa Opioid Antagonist (2-Methyl- N -((2-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl) propan-1-amine, PF-4455242 J. Med. Chem. 54, 5868-5877
33. Grimwood, S., Lu, Y., Schmidt, A. W., Vanase-Frawley, M. A., Sawant-Basak, A., Miller, E., McLean, S., Freeman, J., Wong, S., McLaughlin, J. P., and Verhoest, P. R. (2011) Pharmacological characterization of 2-methyl- N -((2-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for kappa opioid receptors J. Pharmacol. Exp. Ther. 339, 555-566
34. Peters, M. F., Zacco, A., Gordon, J., Maciag, C. M., Litwin, L. C., Thompson, C., Schroeder, P., Sygowski, L. A., Piser, T. M., and Brugel, T. A. (2011) Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity Eur. J. Pharmacol. 661, 27-34
35. Beardsley, P. M., Pollard, G. T., Howard, J. L., and Carroll, F. I. (2010) Effectiveness of analogs of the kappa opioid receptor antagonist (3 R)-7-hydroxy- N -((1 S)-1-{[(3 R,4 R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1- piperidinyl ]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats Psychopharmacology 210, 189-198
36. Eans, S. O., Ganno, M. L., Reilley, K. J., Patkar, K. A., Senadheera, S. N., Aldrich, J. V., and McLaughlin, J. P. (2013) The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration Br. J. Pharmacol. 169, 426-436
37. Munro, T., Berry, L., Van't Veer, A., Beguin, C., Carroll, F., Zhao, Z., Carlezon, W., and Cohen, B. (2012) Long-acting kappa opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity BMC Pharmacol. 12, 5
38. Patkar, K. A., Wu, J., Ganno, M. L., Singh, H. D., Ross, N. C., Rasakham, K., Toll, L., and McLaughlin, J. P. (2013) Physical Presence of Nor-Binaltorphimine in Mouse Brain over 21 Days after a Single Administration Corresponds to Its Long-Lasting Antagonistic Effect on κ-Opioid Receptors J. Pharmacol. Exp. Ther. 346, 545-554
39. Emmerson, P. J., Clark, M. J., Mansour, A., Akil, H., Woods, J. H., and Medzihradsky, F. (1996) Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor J. Pharmacol. Exp. Ther. 278, 1121-1127
40. Lee, K. O., Akil, H., Woods, J. H., and Traynor, J. R. (1999) Differential binding properties of oripavines at cloned mu- and delta-opioid receptors Eur. J. Pharmacol. 378, 323-330
41. Clark, M. J., Emmerson, P. J., Mansour, A., Akil, H., Woods, J. H., Portoghese, P. S., Remmers, A. E., and Medzihradsky, F. (1997) Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor J. Pharmacol. Exp. Ther. 283, 501-510
42. Traynor, J. R. and Nahorski, S. R. (1995) Modulation by mu-opioid agonists of guanosine-5-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells Mol. Pharmacol. 47, 848-854
43. Kenakin, T. P. (2009) A pharmacology primer: theory, applications and methods, Elsevier Academic Press, San Diego.
44. Irwin, S. (1968) Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse Psychopharmacologia 13, 222-257
45. Burke, T. F., Woods, J. H., Lewis, J. W., and Medzihradsky, F. (1994) Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice J. Pharmacol. Exp. Ther. 271, 715-721
46. Clark, R. A., Shoaib, M., Hewitt, K. N., Stanford, S. C., and Bate, S. T. (2012) A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments J. Psychopharmacol. 26, 1136-1142